Salbutamol
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Salbutamol: From Reversible Airway Obstruction (Asthma/COPD) to Papillary Conjunctivitis
One-Sentence Summary
Salbutamol is a beta-2 agonist bronchodilator used for asthma and COPD. The TxGNN model predicts it may be effective for papillary conjunctivitis, but there are 0 clinical trials and 0 publications supporting this direction, so it is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the supplied registration data. Salbutamol is generally used for reversible airway obstruction (asthma/COPD) |
| Predicted New Indication | Papillary conjunctivitis |
| TxGNN Prediction Score | 99.996% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 10 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known pharmacology, salbutamol is a beta-2 adrenergic agonist. Its efficacy in airway obstruction is well established, and mechanistically it may be applicable to allergic eye inflammation.
The only rationale available is weak and theoretical. Beta-2 receptor stimulation can reduce mast cell mediator release, and mast cells drive allergic ocular inflammation. Nothing in the retrieved data tests or confirms this for papillary conjunctivitis. The high TxGNN score reflects a knowledge-graph pattern, not clinical proof.
For context, the same Evidence Pack contains preclinical papers on a related condition, atopic conjunctivitis. In guinea pigs, topical salbutamol suppressed immediate allergic conjunctivitis. Other work reported topical anti-inflammatory activity of beta-2 agonists in the conjunctiva. This is animal data for a different diagnosis, so it offers only indirect support.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
Salbutamol is marketed in South Africa under 10 SAHPRA registrations. The five main registrations are below. Approved indication text was not captured in the registration data, so it is not shown.
| Registration Number | Product Name | Dosage Form |
|---|---|---|
| Reg. No. 30/10.2.2/0200 | Asthavent | Syrup |
| Reg. No. 35/10.2/0142 | Vari-salbutamol syrup | Syrup |
| Reg. No. A39/10.2.1/0482 | Asthavent Respules | Nebuliser |
| Reg. No. 29/10.2.1/0015 | Combivent | Inhaler |
| Reg. No. 30/10.2.1/0032 | Airomir Autohaler | Inhaler |
The dosage forms across all registrations are syrup, nebuliser, inhaler, vial and tablet. None is an ophthalmic product, so a topical eye formulation would be a new development.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting trials or literature (L5). The mechanistic link is theoretical, and no registered South African product is suitable for ocular use.
To proceed, the following is needed:
- Human interventional or observational evidence in papillary or allergic conjunctivitis. The related guinea pig data would need to be translated into clinical studies.
- Detailed mechanism of action data (MOA).
- SAHPRA package insert warnings and contraindications for safety screening.
- A feasibility assessment of an ophthalmic formulation and route.
Other predictions in this Evidence Pack, such as bronchitis (L3) and obstructive lung disease (L2), have stronger evidence. The latter is likely an established use rather than true repurposing, so they may be better priorities for review.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.